Applied Dna Sciences (BNBX) and Its Competitors Critical Analysis

Applied Dna Sciences (NASDAQ:BNBX) is one of 854 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Applied Dna Sciences to similar businesses based on the strength of its valuation, profitability, dividends, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Applied Dna Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Applied Dna Sciences	-1,647.25%	-349.95%	-283.96%
Applied Dna Sciences Competitors	-9,425.57%	-127.18%	-32.99%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Applied Dna Sciences and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Dna Sciences	1	0	0	0	1.00
Applied Dna Sciences Competitors	9520	14940	44809	1525	2.54

As a group, “Biotechnology” companies have a potential upside of 59.89%. Given Applied Dna Sciences’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Applied Dna Sciences has less favorable growth aspects than its rivals.

Volatility and Risk

Applied Dna Sciences has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Applied Dna Sciences’ rivals have a beta of 1.10, indicating that their average share price is 10% more volatile than the S&P 500.

Institutional and Insider Ownership

22.2% of Applied Dna Sciences shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology” companies are owned by institutional investors. 6.1% of Applied Dna Sciences shares are owned by company insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Dna Sciences and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Applied Dna Sciences	$2.09 million	-$15.16 million	-0.04
Applied Dna Sciences Competitors	$683.67 million	$9.15 million	-10.45

Applied Dna Sciences’ rivals have higher revenue and earnings than Applied Dna Sciences. Applied Dna Sciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Applied Dna Sciences rivals beat Applied Dna Sciences on 11 of the 13 factors compared.

About Applied Dna Sciences

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company’s supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.